Melpo is chemist by training and holds a Master degree (MSc) in Biochemistry and a PhD in Radiochemistry from the National and Kapodistrian University of Athens, Greece. After her studies, she moved to the University Hospital Basel, Switzerland as a Post-Doc, followed by three years at the University Hospital Freiburg, Germany, as senior researcher. She returned to Basel as Head of Quality Control in Radiopharmacy and today she is the Head of the Division of Radiopharmaceutical Chemistry at the University Hospital Basel, Qualified Person (QP) for radiopharmaceuticals and Professor of Radiopharmaceutical Chemistry at the Medical Faculty of the University of Basel. Her work focuses on targeted radiopharmaceuticals for oncological diseases in preclinical and clinical settings. She has been using peptides and small molecules in combination with different radioisotopes, to achieve all-in-one diagnosis and therapy, in what is known as theragnostics. She and her group have expertise in the entire spectrum of theragnostics’ development, from the design and synthesis to preclinical development and up to clinical translation and production for human use. Her achievements are linked to theragnostics with somatostatin receptor antagonists for neuroendocrine tumors and to 68Ga- and xCu-radiochemistry that have revealed radiolabelling strategies and radiopharmaceuticals nowadays introduced into the clinic. She has introduced four first-in-man radiopharmaceuticals, with two more on the pipeline. Melpo is a recognized expert in her field and frequently invited lecturer at international conferences and advanced courses of the pharmaceutical industry. She has authored 60+ scientific papers and 6 invited book chapters. She is in the editorial board of the Journal of Nuclear Medicine, EJNMMI Research and Frontiers in Medicine and act as a reviewer for many journals and research funding organisations. She is member of a number of scientific societies, among them the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Society of Molecular Imaging (ESMI).